123 related articles for article (PubMed ID: 34859145)
1.
Murugesan N; Maitituoheti M
Mol Cell Oncol; 2021; 8(5):1984827. PubMed ID: 34859145
[TBL] [Abstract][Full Text] [Related]
2. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
[TBL] [Abstract][Full Text] [Related]
3. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
[TBL] [Abstract][Full Text] [Related]
4. Histone H3 lysine 4 methyltransferase KMT2D.
Froimchuk E; Jang Y; Ge K
Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
[TBL] [Abstract][Full Text] [Related]
5. KMT2D regulates specific programs in heart development via histone H3 lysine 4 di-methylation.
Ang SY; Uebersohn A; Spencer CI; Huang Y; Lee JE; Ge K; Bruneau BG
Development; 2016 Mar; 143(5):810-21. PubMed ID: 26932671
[TBL] [Abstract][Full Text] [Related]
6. Enhancer priming by H3K4 methyltransferase MLL4 controls cell fate transition.
Wang C; Lee JE; Lai B; Macfarlan TS; Xu S; Zhuang L; Liu C; Peng W; Ge K
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11871-11876. PubMed ID: 27698142
[TBL] [Abstract][Full Text] [Related]
7. Loss of Function of the Gene Encoding the Histone Methyltransferase KMT2D Leads to Deregulation of Mitochondrial Respiration.
Pacelli C; Adipietro I; Malerba N; Squeo GM; Piccoli C; Amoresano A; Pinto G; Pucci P; Lee JE; Ge K; Capitanio N; Merla G
Cells; 2020 Jul; 9(7):. PubMed ID: 32668765
[No Abstract] [Full Text] [Related]
8. Lysine methyltransferase Kmt2d regulates naive CD8
Kim J; Nguyen T; Cifello J; Ahmad R; Zhang Y; Yang Q; Lee JE; Li X; Kai Y; De S; Peng W; Ge K; Weng NP
Front Immunol; 2022; 13():1095140. PubMed ID: 36741385
[TBL] [Abstract][Full Text] [Related]
9. Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and SOCS1.
Zhang YH; Tao Q; Zhang WY; Zhao S; Liu WP; Gao LM
Genes Genomics; 2024 Feb; 46(2):203-212. PubMed ID: 37523130
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase KMT2D contributes to the protection of myocardial ischemic injury.
Liu SB; Meng XM; Li YM; Wang JM; Guo HH; Wang C; Zhu BM
Front Cell Dev Biol; 2022; 10():946484. PubMed ID: 35938163
[TBL] [Abstract][Full Text] [Related]
11. H3K4 Methyltransferase Activity Is Required for MLL4 Protein Stability.
Jang Y; Wang C; Zhuang L; Liu C; Ge K
J Mol Biol; 2017 Jun; 429(13):2046-2054. PubMed ID: 28013028
[TBL] [Abstract][Full Text] [Related]
12. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
[TBL] [Abstract][Full Text] [Related]
13. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of lysine demethylation and oxidative phosphorylation.
Dhar SS; Brown C; Rizvi A; Reed L; Kotla S; Zod C; Abraham J; Abe JI; Rajaram V; Chen K; Lee M
bioRxiv; 2023 Nov; ():. PubMed ID: 37961118
[TBL] [Abstract][Full Text] [Related]
14. KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
Sun P; Wu T; Sun X; Cui Z; Zhang H; Xia Q; Zhang D
Biomed Pharmacother; 2019 Jul; 115():108924. PubMed ID: 31100540
[TBL] [Abstract][Full Text] [Related]
15. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.
Koutsioumpa M; Hatziapostolou M; Polytarchou C; Tolosa EJ; Almada LL; Mahurkar-Joshi S; Williams J; Tirado-Rodriguez AB; Huerta-Yepez S; Karavias D; Kourea H; Poultsides GA; Struhl K; Dawson DW; Donahue TR; Fernández-Zapico ME; Iliopoulos D
Gut; 2019 Jul; 68(7):1271-1286. PubMed ID: 30337373
[TBL] [Abstract][Full Text] [Related]
16. Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer.
Li M; Shi M; Xu Y; Qiu J; Lv Q
Cell Transplant; 2021; 30():9636897211027521. PubMed ID: 34705580
[TBL] [Abstract][Full Text] [Related]
17. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.
Li W; Wu L; Jia H; Lin Z; Zhong R; Li Y; Jiang C; Liu S; Zhou X; Zhang E
Cell Mol Biol Lett; 2021 Nov; 26(1):45. PubMed ID: 34758724
[TBL] [Abstract][Full Text] [Related]
18. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
[TBL] [Abstract][Full Text] [Related]
19. KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis.
Lin-Shiao E; Lan Y; Coradin M; Anderson A; Donahue G; Simpson CL; Sen P; Saffie R; Busino L; Garcia BA; Berger SL; Capell BC
Genes Dev; 2018 Jan; 32(2):181-193. PubMed ID: 29440247
[TBL] [Abstract][Full Text] [Related]
20. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription.
Wang SP; Tang Z; Chen CW; Shimada M; Koche RP; Wang LH; Nakadai T; Chramiec A; Krivtsov AV; Armstrong SA; Roeder RG
Mol Cell; 2017 Jul; 67(2):308-321.e6. PubMed ID: 28732206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
